{"entity":{"id":"idea-reg-nonprofit-generic-chemo-manufacturer","kind":"idea","name":"A non-profit manufacturer for generic cancer drugs in chronic shortage","aka":[],"tldr":"Cheap, essential chemotherapy drugs like cisplatin run out because making them is not profitable enough. A non-profit maker could guarantee supply at a fair price.","summary":"The 2023 US shortages of cisplatin and carboplatin, and recurrent shortages of methotrexate, vincristine and other generic oncology drugs, arise from thin margins, concentrated manufacturing and quality failures at single plants. Civica Rx, a non-profit founded by US health systems, has shown that a mission-driven manufacturer with long-term hospital contracts can stabilise supply of generic hospital injectables. The proposal is a non-profit oncology generics manufacturer or a Civica oncology division, with multi-year purchase commitments from health systems and dual-sourced active ingredients, initially for the ten most shortage-prone oncology injectables.","asOf":"2026-09-08","links":[{"label":"Civica Rx","url":"https://civicarx.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Health systems contracting with the non-profit manufacturer experience at least 80% fewer shortage days for covered oncology drugs and pay prices within 20% of prevailing generic prices.","rationale":"Shortages are a market failure of under-investment in redundancy for low-margin products; a manufacturer whose objective is supply reliability rather than margin, backed by demand guarantees, corrects the incentive.","test":"Fund production of five shortage-prone oncology injectables with commitments from 50 hospitals and track shortage days and prices against national shortage data for three years.","maturity":"early-clinical","actor":"philanthropy","cost":"large","horizonYears":3},"route":"/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/","neighbours":{"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"roadmap":[{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/"},{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}